other material
confidence high
sentiment positive
materiality 0.75
Seres' SER-155 reduces BSIs 10% vs 42.9% in allo-HSCT Phase 1b; seeks Breakthrough Therapy
Seres Therapeutics, Inc.
- SER-155 cut bloodstream infections to 10% vs 42.9% placebo (p=0.0423) in 34 evaluable patients.
- Antibiotic exposure duration significantly shorter: 9.2 days vs 21.1 days (p=0.0494).
- Febrile neutropenia incidence 65% vs 78.6% (not statistically significant).
- No treatment-related serious adverse events; drug strains engrafted in GI tract.
- Plans to seek FDA Breakthrough Therapy designation and discuss next steps for allo-HSCT.